Cytori Cell Research Institute, Inc. (3750.T)
JPY 904.0
(-0.88%)
JPY 904.0
(-0.88%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.85 Billion JPY | 0.1% |
| 2022 | 2.06 Billion JPY | 56.13% |
| 2021 | 1.32 Billion JPY | -11.42% |
| 2020 | 1.49 Billion JPY | 279.64% |
| 2019 | 393 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 259 Million JPY | -37.55% |
| 2023 Q2 | 543.95 Million JPY | 1.07% |
| 2023 Q1 | 538.22 Million JPY | -15.05% |
| 2023 Q4 | 414.75 Million JPY | -27.03% |
| 2023 Q3 | 568.42 Million JPY | 4.5% |
| 2023 FY | 2.06 Billion JPY | 0.1% |
| 2022 Q3 | 510.69 Million JPY | 7.66% |
| 2022 FY | 2.06 Billion JPY | 56.13% |
| 2022 Q4 | 633.6 Million JPY | 24.07% |
| 2022 Q2 | 474.33 Million JPY | 0.0% |
| 2021 FY | 1.32 Billion JPY | -11.42% |
| 2020 FY | 1.49 Billion JPY | 279.64% |
| 2019 FY | 393 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -44.571% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -221.936% |
| GNI Group Ltd. | 9.32 Billion JPY | 80.08% |
| Linical Co., Ltd. | 2.7 Billion JPY | 31.355% |
| Trans Genic Inc. | 2.15 Billion JPY | 14.022% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | -24.532% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 39.533% |
| AnGes, Inc. | 8.9 Billion JPY | 79.14% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -96.905% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 90.323% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -349.642% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -90.387% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 27.676% |
| CanBas Co., Ltd. | 278 Million JPY | -567.977% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -62.674% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | -2.147% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | -15.789% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 21.781% |
| PeptiDream Inc. | 9.68 Billion JPY | 80.831% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 5.285% |
| Ribomic Inc. | 1.1 Billion JPY | -67.947% |
| SanBio Company Limited | 4.53 Billion JPY | 59.088% |
| Healios K.K. | 3.48 Billion JPY | 46.746% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -60.814% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -39.155% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | -32.314% |
| StemRIM | 2.07 Billion JPY | 10.55% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 5.425% |
| FunPep Company Limited | 313.82 Million JPY | -491.731% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -93.836% |
| Stella Pharma Corporation | 963.98 Million JPY | -92.635% |
| TMS Co., Ltd. | 943.25 Million JPY | -96.869% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -70.372% |
| Cuorips Inc. | 598.11 Million JPY | -210.47% |
| K Pharma,Inc. | 543.94 Million JPY | -241.392% |
| Takara Bio Inc. | 23.9 Billion JPY | 92.232% |
| ReproCELL Incorporated | 1.51 Billion JPY | -22.652% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -56.84% |
| StemCell Institute Inc. | 1.16 Billion JPY | -59.792% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | -21.987% |
| CellSeed Inc. | 804.93 Million JPY | -130.7% |